What does the research show about these ten nootropics?
The evidence behind these ten names ranges from rat experiments and small EEG studies to trials in people with dementia or after stroke. Those are different questions from improving memory or focus in a healthy person. This comparison covers the actual study findings and named safety concerns, without assigning an effectiveness or safety rank. Semax rat gene-expression study, Selank antenatal-hypoxia rat study, L-theanine EEG attention experiment, Choline alfoscerate dementia trial, Phenotropil stroke-rehabilitation report.
Semax: brain research in rats and compounding concerns
Semax is described in FDA's July 2026 briefing as a synthetic seven-amino-acid analogue of an ACTH fragment. A 2014 study analyzed gene expression in rat brain cortex after experimental focal ischemia. That is research on injured animal tissue, not a clinical test of focus or memory in healthy adults. FDA Semax assessment (2026), Semax rat gene-expression study.
FDA identifies aggregation, peptide impurities and potential immune-response concerns for compounded Semax. The Semax guide explains the broader topic; the animal experiment does not establish a human cognitive benefit for a supplier product. FDA compounded-substance safety concerns, Semax rat gene-expression study.
Selank: a specific rat model and an acetate-specific warning
The cited 2008 Selank study examined adult rats that had experienced antenatal hypoxia. It cannot be treated as a healthy-person anxiety or cognitive trial. FDA's separate safety entry names selank acetate, also called TP-7, and identifies aggregation, peptide-impurity and potential immune-response concerns for that compounded material. The acetate qualification identifies the material discussed by FDA, rather than verifying the formulation of a supplier item. Selank antenatal-hypoxia rat study, FDA compounded-substance safety concerns.
Noopept: patients with vascular or traumatic brain disease
A 2009 publication compared Noopept and piracetam in patients with mild cognitive disorders associated with organic brain diseases of vascular and traumatic origin. The comparison concerns those patient groups; it is not a measured memory or focus result for healthy users. Noopept and piracetam clinical-comparison publication.
Phenylpiracetam: stroke-rehabilitation findings
PubChem lists Phenylpiracetam and Phenotropil among the synonyms of Fonturacetam. A 2010 controlled clinical report studied 400 patients with ischemic stroke. The 200 patients in the main group received phenotropil as part of rehabilitation. The report described better restoration of neurological function and daily activities in that group than in the control group. These were post-stroke rehabilitation findings, not a trial of cognitive enhancement in healthy users. PubChem fonturacetam synonyms, Phenotropil stroke-rehabilitation report.
Aniracetam: a six-month Alzheimer-type dementia trial
A 1991 double-blind, randomized, placebo-controlled study tested aniracetam for six months in 109 elderly patients with probable Alzheimer-type dementia and mild to moderate cognitive impairment. It reported better psychobehavioural measures than placebo at the end of the study. The finding concerns that dementia population and those measures; it is not a demonstrated benefit for healthy-person memory or exam performance. Aniracetam dementia trial.
Modafinil: wakefulness indications and serious-rash risk
The US modafinil label indicates improvement of wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift work disorder. That is a sleepiness-related indication, not an indication for healthy studying or general memory enhancement. Modafinil prescribing information.
The label warns about serious rash requiring hospitalization and treatment discontinuation. Headache, nausea, nervousness, anxiety and insomnia are among adverse reactions reported more commonly than with placebo in modafinil trials. The named indication does not remove those risks. Modafinil prescribing information.
Alpha-GPC: choline alfoscerate research in dementia
Choline alfoscerate is identified in the cited literature as l-alpha glycerylphosphorylcholine, abbreviated alpha-GPC. A 2003 double-blind, randomized, placebo-controlled trial enrolled 261 patients with mild to moderate Alzheimer-type dementia and followed cognitive measures over 180 days. Alpha-GPC terminology in the original publication, Choline alfoscerate dementia trial.
That study reported statistically significant between-treatment differences in ADAS-Cog and several other assessment scores after 90 and 180 days. The measured outcomes were in patients with dementia; the trial does not establish a general cognitive benefit for healthy supplement users. Choline alfoscerate dementia trial.
L-theanine: EEG findings in thirteen participants
The cited attention experiment recorded EEG in 13 neurologically normal people during a demanding visual-spatial attention task. Background alpha-band activity was reduced relative to placebo, while cue-related anticipatory alpha effects were not measurably altered. These are named electrical-activity endpoints. A change in an EEG measure is not the same outcome as improved memory or a broad benefit for concentration. L-theanine EEG attention experiment.
Bacopa: acute null findings and a separate older-adult trial
A 2001 randomized, double-blind acute Bacopa extract experiment in healthy adults assigned 18 people to extract and 20 to placebo. Testing before and two hours after administration found no significant changes on the tested measures. That acute experiment does not describe a 12-week treatment effect. Acute Bacopa extract experiment.
A different 2008 randomized, double-blind, placebo-controlled extract study recruited 54 adults aged 65 or older without clinical signs of dementia; 48 completed the 12-week study. It found improved delayed word recall and Stroop results relative to placebo, but no effects on divided attention or the WAIS digit task. Reported adverse events were mainly stomach upset. The selective findings and side effects give a more precise picture than calling Bacopa a general memory enhancer. Bacopa older-adult trial (2008).
Rhodiola: uncertain usefulness and possible side effects
NCCIH concludes that reliable evidence is insufficient to determine whether rhodiola or its components are useful for a health-related purpose, with most human research rated low to moderate quality. Its listed possible side effects include dizziness, headache, insomnia, dry mouth or excess saliva. A popularity label or an adaptogen description would not resolve that evidence limitation. NCCIH rhodiola evidence and safety.
Which findings answer a healthy-user cognition question?
The dementia and stroke reports concern diagnosed patient populations. The Semax and Selank references concern animal models, and the L-theanine experiment measured EEG. Even within the Bacopa research, the acute healthy-adult experiment and the longer older-adult trial had different time frames and results. These studies cannot be combined into one score for how well a substance improves a healthy person's cognition. Aniracetam dementia trial, Choline alfoscerate dementia trial, Phenotropil stroke-rehabilitation report, Semax rat gene-expression study, Selank antenatal-hypoxia rat study, L-theanine EEG attention experiment, Acute Bacopa extract experiment, Bacopa older-adult trial (2008).
